Conservative multimodal management of a primitive neuroectodermal tumor of the thyroid

3Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Primitive neuroectodermal tumors (PNET) represent 1% of sarcomas. Head and neck peripheral PNETs have an intermediate prognosis between abdominopelvic disease and extremities. We here report the case of a 40-year old male who presented with primitive neuroectodermal tumor of the thyroid and was treated by multimodal treatment, including surgery, chemotherapy and intermediate dose radiotherapy. The patient is alive and fit with a functional larynx at 27 months. Multimodal treatments yield five-year survival rates of about 60%. Major drug regimens use vin-cristine, doxorubicin, ifosfamide or cyclophos-phamide, dactinomycin and/or etoposide. Complete surgical excision is undertaken whenever possible to improve long-term survival. However, the relative radiosensitivity of tumors of the Ewing family, suggest multi-modal treatment including adjuvant conformal radiotherapy in case of positive margins or poor response to chemotherapy rather than resection with 2-3 cm margins, which would imply laryngeal sacrifice for thyroid tumors. The role of expert rare tumor networks is crucial for optimal decision-making and management of such rare tumors on a case by case basis. © J. Thariat et al., 2013.

Cite

CITATION STYLE

APA

Natale, R., Thariat, J., Vedrine, P. O., Bozec, L., Peyrottes, I., Marcy, P. Y., … Thyss, A. (2013). Conservative multimodal management of a primitive neuroectodermal tumor of the thyroid. Rare Tumors, 5(2), 75–78. https://doi.org/10.4081/rt.2013.e20

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free